PATIENTS diagnosed with both rheumatoid arthritis (RA) and cancer face complex treatment decisions, and many want clearer, more tailored information to help them navigate the risks and benefits of continuing RA medications, according to a new qualitative study.
Researchers interviewed 20 patients from a cancer centre to explore their beliefs, preferences, and informational needs related to RA treatment during or after cancer diagnosis. Most participants were women, with an average age of 60 years. The study found that while patients generally felt supported by their doctors, many harboured concerns about how RA drugs might influence cancer recurrence or interfere with cancer therapies.
Some patients were hesitant about continuing biologics due to fears of immunosuppression, yet most said they would consider taking a drug even if its cancer-related effects were uncertain, emphasising the role of trust in their healthcare providers. Patients also highlighted the importance of receiving balanced information about drug efficacy, side effects, interactions, and cost.
Crucially, the findings suggest that current clinical conversations may not fully address patient concerns or align with individual preferences around decision-making. The authors recommend using these insights to develop targeted educational materials that promote shared decision-making.
As cancer survivorship increases and treatment complexity grows, understanding patient perspectives will be essential to delivering care that supports both safety and quality of life.
Reference
Ruiz JI et al. Beliefs, preferences, and informational needs of patients with rheumatoid arthritis and concomitant cancer: a qualitative study. BMC Rheumatol. 2025;DOI: 10.1186/s41927-025-00526-7.
